Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D062108 | May-Thurner Syndrome NIH | 1.00 |
| D014689 | Venous Insufficiency NIH | 1.00 |
| D020246 | Venous Thrombosis NIH | 0.29 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0005293 | Venous insufficiency HPO | 1.00 |
| HP:0002625 | Deep venous thrombosis HPO | 0.29 |
Navigate: Correlations HPO
There is one clinical trial.
This is a prospective, multi-center, single-arm, non-blinded clinical trial designed to investigate the safety and efficacy of the Vesper DUO Venous Stent System as compared to a pre-defined performance goal (PG) established from published, peer reviewed scientific literature related to stenting of iliofemoral venous outflow obstructions.
Description: Freedom from major adverse events (MAEs) at 30 days post index procedure, as adjudicated by the Clinical Events Committee (CEC) or Core Laboratory, including: Device or procedure-related death Device or procedure-related bleed at the target vessel and/or the target lesion or at the access site requiring surgical or endovascular intervention or blood transfusion of ≥2 units Device or procedure-related venous injury occurring in the target vessel and/or the target lesion or at the access site requiring surgical or endovascular intervention Major amputation of the target limb Clinically significant pulmonary embolism (PE), confirmed by CT angiography Stent embolization outside of the target vessel Presence of new thrombus within the stented segment
Measure: Safety - Freedom from major adverse events (MAEs) at 30 days Time: 30 daysDescription: Primary patency of stented segment at 12 months defined as freedom from: Duplex Ultrasound (DUS) core laboratory adjudicated stenosis or occlusion >50% within the stented segment. If DUS shows >50% stenosis or occlusion, confirmation by diagnostic intravascular ultrasound (IVUS) is required. CEC adjudicated clinically driven target lesion reintervention (CD-TLR) defined as endovascular or surgical procedure for new, recurrent, or worsening symptoms and core lab adjudicated >50% stenosis or occlusion within the stented segment confirmed by diagnostic IVUS
Measure: Efficacy - Primary patency of stented segment at 12 months Time: 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports